TRUE™ Vascular Graft
Synthetic vascular grafts currently used in clinic have poor long term outcomes and low patency rates. Hyperplasia, calcification, foreign body immune response, infection, and atheroma formation are commonly encountered limiting the use of synthetic grafts, with none available for small diameter applications like coronary bypass.
TRUE™ Vascular Graft is 100% biological with no synthetic raw materials. Through our quality controlled manufacturing process, TRUE™ graft with diameters in range from 3.0 to 25.0 mm are developed to match anatomical sites.
Extensive preclinical in vivo testing conducted by Vascudyne™ and the University of Minnesota in sheep and baboons have been published in peer-reviewed journals. These studies have demonstrated that TRUE™ Vascular Grafts are:
- Long-term patency
- Regenerative with proven recellularization and remodeling
- Mechanical properties comparable to native blood vessels
- Elicit negligible immune/foreign body response
- Able to adapt and grow with the graft recipient
TRUE™ Vascular Grafts are completely cell-derived matrix, decellularized after in vitro bioreactor culture, sterilized, and stored for off-the-shelf use. Recellularization and regeneration take place after implantation by the host cells with organized cell and matrix composition.
TRUE™ Vascular Graft technology is well suited for several anatomical sites:
• Arteriovenous grafts
• Coronary bypass
• Peripheral bypass
• Diabetic vascular repair
• Trauma repair
TRUE™ Graft has the potential to provide a much-needed long term solution for hemodialysis patients based on preclinical studies. Previous results from a preclinical baboon model showed that 12-cm long grafts were completely regenerated and endothelialized after 6 months post-implantation (Syedain et al, 2017).
Coronary Artery Bypass Graft
Vascudyne’s CSO presents at the Heart Valve Society Meeting on tissue remodeling of engineered valved conduit evaluated at 52 weeks in the growing lamb
Copyright 2021 | Vascudyne, Inc.